Back to discover
Disease

Pruritus

Late-stage therapeutic developmentEmerging researchRising momentum
6
Publications
20
Clinical trials
4
Related conditions
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Clinical Milestones8View
Activity timeline8

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies

Approval — Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALG… (2024)

Approval — Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with ch… (2022)

Approval — Livmarli is indicated for the treatment of: Cholestatic pruritus in patients with Alagil… (2022)

Clinical trials

13 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
14
Late-stage
6
Completed
Late-stage studies
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaApprovalOdevixibat sesquihydrate· Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older (see sections 4.4 and 5.1). source ↗
2022emaApprovalMaralixibat chloride· Livmarli is indicated for the treatment of: Cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older, Progressive familial intrahepatic cholestasis (PFIC) in patients 3 months of age and older. Livmarli tablets is indicated in adults and adolescents 12 years and older for the treatment of: Cholestatic pruritus in patients with Alagille syndrome (ALGS), Progressive familial intrahepatic cholestasis (PFIC). source ↗
2022emaApprovalDifelikefalin· Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

6 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20172024
Most influential
Recent publications
Major themes4
  • Cytokines1
  • Dermatitis, Atopic1
  • Eczema1
  • Immune Checkpoint Inhibitors1
Leading journals6
  • Acta dermato-venereologica1
  • Clinical cancer research : an official journal of the American Association for Cancer Research1
  • JAMA dermatology1
  • Journal of the European Academy of Dermatology and Venereology : JEADV1
  • The Journal of investigative dermatology1
  • The New England journal of medicine1
Leading researchers8
  • Gieler U2
  • Wollenberg A2
  • Albornoz C1
  • Armstrong AW1
  • Bang A1
  • Barbarot S1
  • Berdyshev E1
  • Blauvelt A1
Affiliations (unnormalised)6
  • Aarhus University Hospital1
  • Bern University Hospital1
  • Centre Hospitalier Universitaire Vaudois1
  • Christiane-Kühne Center for Allergy Research and Education (CK-Care)1
  • Department of Pathology and Laboratory Medicine1
  • Erasmus MC University Medical Center1

Related conditions

4 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Pruritus is an intense itching sensation that creates an urge to rub or scratch the skin for relief. It is a common symptom in medicine and may occur as an isolated complaint or as part of another disease process. Chronic pruritus can arise from dermatologic or non-dermatologic conditions and may be multifactorial.

Causes

Pruritus may result from dermatological disease or from systemic, neurological, or psychiatric disease. It can also occur as a side effect of medications. In some cases, no single cause is identified and the itch is multifactorial.

Pathophysiology

The supplied grounding does not describe a specific biological mechanism for pruritus beyond the symptom of itch itself. It indicates that chronic pruritus can originate from skin disease, non-diseased skin, systemic illness, neurological disease, psychiatric disease, or medication effects. A precise diagnostic work-up is needed because the underlying mechanism depends on the cause.

Risk factors

Risk is increased by the presence of underlying skin disease, systemic disease, neurological disease, psychiatric disease, or exposure to medications that can cause itch. Chronic pruritus is reported more frequently in certain patient populations, including haemodialysis patients and patients with skin diseases such as urticaria and atopic dermatitis. The grounding also notes that chronic pruritus is common in the general population over a lifetime.

Current standard of care

Management of chronic pruritus includes treatment of the underlying disease. It also includes topical treatment modalities and symptomatic therapy, but the supplied grounding does not specify drug classes beyond this general approach. A precise diagnostic work-up is part of standard management.

AI-generated summary grounded in MeSH and 1 peer-reviewed source. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.